Advertisement
U.S. Markets closed

Optimi Health Corp. (OPTHF)

OTC Markets OTCQX - OTC Markets OTCQX Delayed Price. Currency in USD
0.1550+0.0050 (+3.45%)
At close: 03:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1500
Open0.1500
Bid0.1230 x 0
Ask0.1471 x 0
Day's Range0.1500 - 0.1550
52 Week Range0.1100 - 0.4300
Volume39,533
Avg. Volume20,010
Market Cap14.673M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Optimi Health Announces Leadership Transition

    Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons."During his three years of leadership, Bill has played a key role in bringing Optimi's GMP psychedelics to ma

  • Newsfile

    Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial

    Trial to study Major Depressive Disorder using Optimi's GMP natural psilocybin capsules in conjunction with therapy Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics pharmaceuticals specializing in botanical psilocybin and MDMA, is pleased to announce the receipt of a No Objection Letter (NOL) from Health Canada. This authoriz

  • Newsfile

    Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment

    Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the inaugural export of it's GMP-validated MDMA capsules to Australia for the treatment of PTSD, along with a series of notable corporate developments.MDMA Capsule Export to Austra